GRIND/ALMOND investigations on CysLT1 receptor antagonists of the quinolinyl(bridged)aryl type

被引:26
作者
Benedetti, P
Mannhold, R
Cruciani, G
Ottaviani, G
机构
[1] Univ Perugia, Dipartimento Chim, Lab Chemiometr, I-06123 Perugia, Italy
[2] Univ Dusseldorf, Mol Drug Res Grp, Dept Laser Med, D-40225 Dusseldorf, Germany
关键词
CysLT(1) receptor antagonists; grid independent descriptors (GRIND); PLS analysis; PLS discriminant analysis;
D O I
10.1016/j.bmc.2004.04.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the current routes in developing antiasthmatics is CysLT(1) receptor antagonism. For a training set of 54 CysLT(1) receptor antagonists of the quinolinyl(bridged)aryl type we developed chemometric QSAR models applying GRID independent descriptors (= GRIND). PLS analysis resulted in a two-component model explaining 67% of the variance for CysLT(1) receptor binding (r(2) = 0.67, SDEC = 0.47, q(2) = 0.54). GRIND variables 11-50 and 22-55 are responsible for high-affinity binding; variable 11-62 is detrimental. The predictivity of the above chemometric model is tested with a set of 69 CysLT(1) receptor antagonists, exhibiting varying chemical similarity to the training set. Nearly 50% of the test set are quite well predicted. The quality of prediction coincides in part with chemical subclassification: phenylene bridged compounds are quite well predicted, for structures with bridging heterocycles predictions are rather poor. For explaining the outlier behavior, a PLS discriminant analysis including the training set and the strongest outliers of the test set was performed. The scores plot of discriminant PLS shows an almost complete separation between the two subsets. A PLS coefficients plot explains which GRIND variables are important for the discrimination between the training set and the outliers of the test set. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3607 / 3617
页数:11
相关论文
共 23 条
[1]  
[Anonymous], 2002, GRID VERS 20
[2]   ANTIINFLAMMATORY THERAPY FOR ASTHMA [J].
BARNES, PJ .
ANNUAL REVIEW OF MEDICINE, 1993, 44 :229-242
[3]  
BARNES PJ, 1988, PHARMACOL REV, V40, P49
[4]   ASTHMA - WHAT IS THERE LEFT TO FIND OUT [J].
BARNES, PJ .
BRITISH MEDICAL JOURNAL, 1993, 307 (6908) :814-815
[5]  
BARNES PJ, 1992, EUR RESPIR J, V5, P1126
[6]   Modulators of leukotriene biosynthesis and receptor activation [J].
Brooks, CDW ;
Summers, JB .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) :2629-2654
[7]   ROLE OF INFLAMMATORY MEDIATORS IN ASTHMA [J].
CHUNG, KF ;
BARNES, PJ .
BRITISH MEDICAL BULLETIN, 1992, 48 (01) :135-148
[9]  
COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283
[10]   CHARACTERIZATION OF THE LEUKOTRIENE D4 RECEPTOR IN DIMETHYLSULFOXIDE-DIFFERENTIATED-U937 CELLS - COMPARISON WITH THE LEUKOTRIENE-D4 RECEPTOR IN HUMAN LUNG AND GUINEA-PIG LUNG [J].
FREY, EA ;
NICHOLSON, DW ;
METTERS, KM .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1993, 244 (03) :239-250